Pulmonx Corporation (LUNG) Fair Value 2026

LUNG · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.5 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-13, Pulmonx Corporation (LUNG) trades at $1.46, approximately 209% above CirclFi’s Bayesian DCF fair value of $0.47. QOC: 7.5/10. Value Trap Risk: 12/100 (SAFE). 11/13 models active.

Key Facts

Ticker
LUNG
Price
$1.46
Quality Score
7.5/10
Value Trap Risk
12/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +153.7% upside with 24% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($1.46)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.47 -67.6%
Earnings Power Value
Medium Conviction
$3.65 +149.7%
CUCE Ensemble
Low Conviction
$2.96 +102.6%
First Chicago
Medium Conviction
$3.70 +153.7%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Pulmonx Corporation (LUNG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pulmonx Corporation's intrinsic value is estimated at a composite fair value of $2.87. At a current market price of $1.46, 10 of 11 active valuation models identify upside potential, projecting an average implied return of +96.8%. Notably, Regime Cross sees the most upside at +212.3% (fair value: $4.56), while Bayesian DCF is the most conservative at -67.6% ($0.47). The spread between these extremes — +279.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About LUNG?

11 of 13 models are currently active for LUNG. Of these, 10 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates LUNG's intrinsic value at $0.47, implying -67.6% downside from the current price. See which stocks rank higher →

How Does LUNG Rank in Surgical & Medical Instruments & Apparatus?

Among 111 Surgical & Medical Instruments & Apparatus stocks, LUNG ranks #29 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

Pulmonx Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is LUNG a Value Trap?

CirclFi's Value Trap algorithm assigns LUNG a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Pulmonx Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Pulmonx Corporation scores 7.5 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +279.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LUNG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LUNG's 11 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pulmonx Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About Pulmonx Corporation

What is Pulmonx Corporation's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Pulmonx Corporation (LUNG) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.47. The Quality of Company score is 7.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LUNG overvalued or undervalued right now?

At $1.46, 10 of 11 active models suggest LUNG may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Pulmonx Corporation's business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 7.5 mean for LUNG?

Pulmonx Corporation's QOC of 7.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on LUNG?

CirclFi analyzes LUNG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is LUNG a value trap in 2026?

Pulmonx Corporation's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on LUNG.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access